3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

Part of paid clinical trials in Detroit, Michigan.

Sponsor
Barbara Ann Karmanos Cancer Institute
Study ID
NCT00935090
Status
Recruiting
Apply to this trial

Conditions

  • Brain and Central Nervous System Tumors
  • Chronic Myeloproliferative Disorders
  • Leukemia
  • Lymphoma
  • Lymphoproliferative Disorder
  • Multiple Myeloma and Plasma Cell Neoplasm
  • Myelodysplastic Syndromes
  • Myelodysplastic/Myeloproliferative Neoplasms
  • Unspecified Adult Solid Tumor, Protocol Specific

Eligibility Criteria

Sex
ALL
Age
18 Years - 120 Years
Healthy Volunteers
Not accepted

Interventions

  • 3'-deoxy-3'-[18F]fluorothymidine — DEVICE
    The tracer compound \[F-18\] FLT will be injected into the patient's veins in a small volume of normal saline solution. The PET scan data collection is started immediately and is continued for 2 hours. This procedure will measure tumor growth within the body. Blood may be withdrawn (through the catheters) up to a total volume of 30 milliliters (or 2 tablespoons) for each scan. A urine sample may be collected at the end of the imaging of the tracer compound to analyze its breakdown products.

Study Details

RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-\[18F\] fluorothymidine (FLT) PET imaging, may help find and diagnose cancer. It may also help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This phase I trial is studying FLT PET imaging in patients with cancer.

Key Dates

Start date
Sep 30, 2009
Status verified
Jul 2025
Primary completion
May 31, 2027
Completion
May 31, 2028

Arms

  • Experimental: 3'-deoxy-3'-[18F]fluorothymidine
    The PET scan data collection is started immediately and is continued for 2 hours. This procedure will measure tumor growth within the body.

Primary Outcome Measure

Measurement of the uptake and retention of 3'-deoxy-3'-[18F] fluorothymidine (FLT) in tumors and normal organs [ Time Frame: at time of PET or CT PET Scan ]

Locations (1)

FacilityCityStateZIPSite coordinators
Barbara Ann Karmanos Cancer InstituteDetroitMichigan48201-1379
Clinical Trials Office - Barbara Ann Karmanos Cancer Institute
800-527-6266
Elisabeth Heath, M.D. (SUB_INVESTIGATOR)
Otto Muzik, Ph.D. (SUB_INVESTIGATOR)
Mohammed N Al Hallak, M.D (SUB_INVESTIGATOR)
Hirva Mamdani, M.D (SUB_INVESTIGATOR)
Ammar Sukari, M.D. (SUB_INVESTIGATOR)
Huailei Jiang, Ph.D. (SUB_INVESTIGATOR)

Find similar trials in Detroit, MI

By condition
Leukemia (other)
By specialty
OncologyBlood cancer
By research site
Barbara Ann Karmanos Cancer Institute· Detroit, MI

Related Studies